Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases
- 9 June 1998
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (14) , 2588-2603
- https://doi.org/10.1021/jm980123i
Abstract
3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. By modifying the 3-substituted indolin-2-ones, we have identified compounds which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells. Structure−activity analysis for these compounds and their relative potency and selectivity to inhibit particular RTKs has determined that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones containing bulky group(s) in the phenyl ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compound containing an extended side chain at the C-3 position of the indolin-2-one (16) exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs. Recent published crystallographic data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compounds may bind in the ATP binding pocket of RTKs. The structure−activity analysis supports the use of subsets of these compounds as specific chemical leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.Keywords
This publication has 11 references indexed in Scilit:
- Inhibitors of tyrosine kinaseCurrent Opinion in Oncology, 1997
- Protein tyrosine kinase inhibitors in cancer treatmentExpert Opinion on Therapeutic Patents, 1997
- Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with InhibitorsScience, 1997
- Receptor tyrosine kinases as targets for inhibition of angiogenesisDrug Discovery Today, 1997
- 4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine KinaseJournal of Medicinal Chemistry, 1996
- Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor ReceptorJournal of Medicinal Chemistry, 1996
- A New Efficient and Mild Synthesis of 2-Sxindoles by One-Pot Wolff-Kishner Like Reduction of Isatin DerivativesSynthetic Communications, 1994
- Growth factors and tyrosine protein kinases in normal and malignant melanocytesCancer and Metastasis Reviews, 1991
- Signal transduction by receptors with tyrosine kinase activityPublished by Elsevier ,1990
- The Identification of Aldose Sugars by their Mercaptal AcetatesJournal of the American Chemical Society, 1945